PACB
Income statement / Annual
Last year (2023), Pacific Biosciences of California, Inc.'s total revenue was $200.52 M,
an increase of 56.29% from the previous year.
In 2023, Pacific Biosciences of California, Inc.'s net income was -$306.74 M.
See Pacific Biosciences of California, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$200.52 M
|
$128.30 M
|
$130.51 M
|
$78.89 M
|
$90.89 M
|
$78.63 M
|
$93.47 M
|
$90.71 M
|
$92.78 M
|
$60.59 M
|
| Cost of Revenue |
$160.18 M |
$79.27 M |
$71.65 M |
$46.33 M |
$56.32 M |
$53.53 M |
$58.81 M |
$46.55 M |
$39.33 M |
$37.19 M |
| Gross Profit |
$40.35 M |
$49.04 M |
$58.86 M |
$32.57 M |
$34.58 M |
$25.10 M |
$34.66 M |
$44.16 M |
$53.45 M |
$23.40 M |
| Gross Profit Ratio |
0.2 |
0.38 |
0.45 |
0.41 |
0.38 |
0.32 |
0.37 |
0.49 |
0.58 |
0.39 |
| Research and Development
Expenses |
$187.17 M
|
$193.00 M
|
$112.90 M
|
$64.15 M
|
$59.63 M
|
$62.59 M
|
$65.32 M
|
$67.62 M
|
$60.44 M
|
$48.23 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.49 M
|
$59.12 M
|
$47.79 M
|
$45.19 M
|
$38.03 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$163.54 M
|
$160.85 M
|
$124.12 M
|
$72.80 M
|
$75.49 M
|
$63.49 M
|
$59.12 M
|
$47.79 M
|
$45.19 M
|
$38.03 M
|
| Other Expenses |
$32.68 M |
$7.64 M |
$93,000.00 |
$2.06 M |
$1.02 M |
$848,000.00 |
$516,000.00 |
$103,000.00 |
$364,000.00 |
-$478,000.00 |
| Operating Expenses |
$350.71 M |
$353.85 M |
$237.02 M |
$136.95 M |
$135.12 M |
$126.08 M |
$124.44 M |
$115.40 M |
$105.63 M |
$86.26 M |
| Cost And Expenses |
$510.89 M |
$433.12 M |
$308.68 M |
$183.28 M |
$191.44 M |
$179.61 M |
$183.25 M |
$161.96 M |
$144.96 M |
$123.45 M |
| Interest Income |
$0.00 |
$14.69 M |
$12.53 M |
$267,000.00 |
$2.61 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$14.34 M |
$14.69 M |
$12.53 M |
$267,000.00 |
$2.61 M |
$2.42 M |
$2.92 M |
$3.23 M |
$2.93 M |
$2.83 M |
| Depreciation &
Amortization |
$32.69 M
|
$17.32 M
|
$11.59 M
|
$9.30 M
|
$9.95 M
|
$7.22 M
|
$8.44 M
|
$3.88 M
|
$3.68 M
|
$4.22 M
|
| EBITDA |
-$277.67 M
|
-$297.18 M
|
-$178.07 M
|
-$102.33 M
|
-$99.52 M
|
-$100.14 M
|
-$89.27 M
|
-$67.27 M
|
-$51.81 M
|
-$59.11 M
|
| EBITDA Ratio |
-1.38 |
-2.32 |
-1.36 |
-1.3 |
-1.09 |
-1.27 |
-0.96 |
-0.74 |
-0.56 |
-0.98 |
| Operating Income Ratio
|
-1.55
|
-2.38
|
-1.37
|
-1.32
|
-1.11
|
-1.28
|
-0.96
|
-0.79
|
-0.31
|
-1.04
|
| Total Other
Income/Expenses Net |
-$7.79 M
|
-$9.43 M
|
-$96.71 M
|
$133.79 M
|
$16.41 M
|
$848,000.00
|
$516,000.00
|
$103,000.00
|
$23.41 M
|
-$478,000.00
|
| Income Before Tax |
-$318.16 M |
-$314.25 M |
-$274.87 M |
$29.40 M |
-$84.13 M |
-$102.56 M |
-$92.19 M |
-$74.38 M |
-$31.70 M |
-$66.16 M |
| Income Before Tax Ratio
|
-1.59
|
-2.45
|
-2.11
|
0.37
|
-0.93
|
-1.3
|
-0.99
|
-0.82
|
-0.34
|
-1.09
|
| Income Tax Expense |
-$11.42 M |
-$17.32 M |
-$93.65 M |
-$6.98 M |
-$6.32 M |
$848,000.00 |
-$5.01 M |
$3.34 M |
-$387,000.00 |
$2.35 M |
| Net Income |
-$306.74 M |
-$296.93 M |
-$181.22 M |
$29.40 M |
-$77.82 M |
-$102.56 M |
-$92.19 M |
-$74.38 M |
-$31.70 M |
-$66.16 M |
| Net Income Ratio |
-1.53 |
-2.31 |
-1.39 |
0.37 |
-0.86 |
-1.3 |
-0.99 |
-0.82 |
-0.34 |
-1.09 |
| EPS |
-1.21 |
-1.32 |
-0.89 |
0.18 |
-0.51 |
-0.76 |
-0.87 |
-0.83 |
-0.42 |
-0.94 |
| EPS Diluted |
-1.21 |
-1.32 |
-0.89 |
0.17 |
-0.51 |
-0.76 |
-0.87 |
-0.83 |
-0.42 |
-0.94 |
| Weighted Average Shares
Out |
$253.63 M
|
$224.46 M
|
$203.62 M
|
$172.96 M
|
$152.53 M
|
$134.95 M
|
$105.68 M
|
$89.15 M
|
$75.61 M
|
$70.48 M
|
| Weighted Average Shares
Out Diluted |
$253.63 M
|
$224.55 M
|
$204.14 M
|
$174.97 M
|
$152.53 M
|
$135.09 M
|
$105.68 M
|
$89.15 M
|
$75.61 M
|
$70.48 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
